Renal function outcomes and kidney biopsy features of living kidney donors with hypertension.

arteriosclerosis glomerular filtration rate hypertension implantation biopsy living kidney donation medium- to long-term outcomes nephrosclerosis proteinuria

Journal

Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240

Informations de publication

Date de publication:
06 2021
Historique:
revised: 11 03 2021
received: 23 12 2020
accepted: 12 03 2021
pubmed: 22 3 2021
medline: 29 6 2021
entrez: 21 3 2021
Statut: ppublish

Résumé

The medium- to long-term outcomes of living kidney donors with hypertension compared to normotensive donors are not well understood, especially with the recent changes in hypertension guidelines. We studied a cohort of 950 living kidney donors using different definitions of hypertension based on either ≥140/90 or ≥130/80 mmHg thresholds and based on either office or ambulatory blood pressure readings. Microstructural features on kidney biopsy at the time of donation were compared using different definitions of hypertension. After adjusting for years of follow-up, age, sex, and baseline eGFR, hypertension (by any definition) did not significantly predict an eGFR < 45 ml/min/1.73 m In programs that accept donors with controlled hypertension, various definitions of hypertension are associated with histological findings in the donated kidney, but none predict a clinically significant decline in kidney function 10 years after donation. These data support allowing healthy individuals with controlled hypertension to donate a kidney. However, donors with office hypertension (≥140/90 mmHg) and nondippers (regardless of hypertension status) are at greater long-term risk for proteinuria, and particularly for these donors, longer follow-up is warranted.

Sections du résumé

BACKGROUND
The medium- to long-term outcomes of living kidney donors with hypertension compared to normotensive donors are not well understood, especially with the recent changes in hypertension guidelines.
METHODS
We studied a cohort of 950 living kidney donors using different definitions of hypertension based on either ≥140/90 or ≥130/80 mmHg thresholds and based on either office or ambulatory blood pressure readings. Microstructural features on kidney biopsy at the time of donation were compared using different definitions of hypertension.
RESULTS
After adjusting for years of follow-up, age, sex, and baseline eGFR, hypertension (by any definition) did not significantly predict an eGFR < 45 ml/min/1.73 m
CONCLUSIONS
In programs that accept donors with controlled hypertension, various definitions of hypertension are associated with histological findings in the donated kidney, but none predict a clinically significant decline in kidney function 10 years after donation. These data support allowing healthy individuals with controlled hypertension to donate a kidney. However, donors with office hypertension (≥140/90 mmHg) and nondippers (regardless of hypertension status) are at greater long-term risk for proteinuria, and particularly for these donors, longer follow-up is warranted.

Identifiants

pubmed: 33745214
doi: 10.1111/ctr.14293
pmc: PMC8279018
mid: NIHMS1716406
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e14293

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK090358
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007013
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States

Informations de copyright

© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Ann Intern Med. 2010 May 4;152(9):561-7
pubmed: 20439574
Hypertension. 2004 Nov;44(5):595-601
pubmed: 15452024
N Engl J Med. 2009 Jan 29;360(5):459-69
pubmed: 19179315
Nephrol Dial Transplant. 2009 Aug;24(8):2400-6
pubmed: 19251741
J Am Soc Nephrol. 2008 Nov;19(11):2047-51
pubmed: 18923054
Transplantation. 2004 Jul 27;78(2):276-82
pubmed: 15280690
Clin J Am Soc Nephrol. 2009 Apr;4(4):830-7
pubmed: 19339424
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1048-1055
pubmed: 31239252
Am J Transplant. 2019 Jul;19(7):1989-1998
pubmed: 30629312
JAMA. 2003 May 21;289(19):2560-72
pubmed: 12748199
BMJ. 2012 Mar 01;344:e1203
pubmed: 22381674
Auton Neurosci. 2001 May 14;88(3):181-6
pubmed: 11474560
Urology. 2005 Nov;66(5):971-5
pubmed: 16286105
Cardiovasc J Afr. 2017 Jan/Feb 23;28(1):14-18
pubmed: 27177043
Hypertens Res. 2019 Mar;42(3):354-361
pubmed: 30546105
J Am Soc Nephrol. 2003 Aug;14(8):2159-67
pubmed: 12874471
Circulation. 1990 Feb;81(2):528-36
pubmed: 2137047
Transplantation. 2014 Jan 15;97(1):104-10
pubmed: 24092387
Nephrol Dial Transplant. 2015 Dec;30(12):2034-9
pubmed: 25888387
J Am Soc Nephrol. 2016 Sep;27(9):2885-93
pubmed: 26888476
Lancet. 2010 Jun 12;375(9731):2073-81
pubmed: 20483451
Kidney Int. 2014 Jul;86(1):162-7
pubmed: 24284516
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
Lancet. 1992 Dec 12;340(8833):1435-6
pubmed: 1360561
JAMA. 2002 Feb 27;287(8):1003-10
pubmed: 11866648
Am J Transplant. 2020 Jan;20 Suppl s1:20-130
pubmed: 31898417
JAMA. 2014 Feb 12;311(6):579-86
pubmed: 24519297
Nephrol Dial Transplant. 2014 Jul;29(7):1399-409
pubmed: 24327566
Transplantation. 2012 Feb 27;93(4):412-7
pubmed: 22217533
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Transplantation. 2018 Oct;102(10):1756-1761
pubmed: 29677075
Am J Kidney Dis. 2016 Jul;68(1):58-67
pubmed: 26857648
Mayo Clin Proc. 2021 Jan;96(1):40-51
pubmed: 33097219
Lancet. 1988 Aug 13;2(8607):397
pubmed: 2899801
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Hypertens Res. 2010 Oct;33(10):1032-7
pubmed: 20668452
Adv Chronic Kidney Dis. 2015 Mar;22(2):102-7
pubmed: 25704346
Am J Kidney Dis. 2004 Jan;43(1):112-9
pubmed: 14712434
Am J Kidney Dis. 2015 Jul;66(1):114-24
pubmed: 25795073
Mayo Clin Proc. 2000 Dec;75(12):1236-42
pubmed: 11126830
Kidney Int. 2020 Jul;98(1):168-175
pubmed: 32331703
JCI Insight. 2017 Oct 5;2(19):
pubmed: 28978800
Transplant Proc. 2003 May;35(3):946-7
pubmed: 12947810
J Am Soc Nephrol. 2015 Jun;26(6):1261-7
pubmed: 25525178
J Am Soc Nephrol. 2017 Jan;28(1):313-320
pubmed: 27401688
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272

Auteurs

Massini A Merzkani (MA)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Aidan Mullan (A)

Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA.

Aleksandar Denic (A)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.

Matthew D'Costa (M)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Ryan Iverson (R)

Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA.

Walter Kremers (W)

Division of Biomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA.

Mariam P Alexander (MP)

Department of Pathology, Mayo Clinic, Rochester, MN, USA.

Stephen C Textor (SC)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Sandra J Taler (SJ)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Mark D Stegall (MD)

William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Joshua Augustine (J)

Cleveland Clinic, Cleveland, OH, USA.

Naim Issa (N)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.
William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USA.

Andrew D Rule (AD)

Division of Nephrology & Hypertension, Mayo Clinic, Rochester, MN, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH